Royalty Pharma plc (RPRX) Operating Margin
- Operating margin · 12 months: Value 59.61%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 59.61% | Operating income / revenue. Period ending 2026-06-30. $1.51B ÷ $2.54B × 100 ≈ 59.61% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 1.51B USD | Operating Income (Loss) |
| Revenue | 2.54B USD | |
| Cost of products and services | (m) | |
| Research and development | 238.64M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.51B | $2.54B | (m) | $238.64M | (m) | 59.61% |
| 2026-03-31 | $1.59B | $2.44B | (m) | $441.29M | (m) | 65.08% |
| 2025-12-31 | $1.56B | $2.38B | (m) | $452.00M | (m) | 65.58% |
| 2025-09-30 | $1.53B | $2.35B | (m) | $402.00M | (m) | 65.22% |
| 2025-06-30 | $1.84B | $2.31B | (m) | $352.00M | (m) | 79.84% |
| 2025-03-31 | $1.90B | $2.26B | (m) | $52.00M | (m) | 83.95% |
| 2024-12-31 | $1.29B | $2.26B | (m) | $2.00M | (m) | 57.10% |
| 2024-09-30 | $1.54B | $2.27B | (m) | $2.00M | (m) | 68.13% |
| 2024-06-30 | $960.19M | $2.24B | (m) | $52.00M | (m) | 42.91% |
| 2024-03-31 | $939.40M | $2.24B | (m) | $52.00M | (m) | 41.96% |
| 2023-12-31 | $1.49B | $2.35B | (m) | $52.00M | (m) | 63.37% |
| 2023-09-30 | $396.60M | $2.32B | (m) | $102.00M | (m) | 17.06% |
| 2023-06-30 | $437.37M | $2.36B | (m) | $77.00M | (m) | 18.52% |
| 2023-03-31 | $566.32M | $2.36B | (m) | $77.11M | (m) | 24.01% |
| 2022-12-31 | $307.06M | $2.24B | (m) | $177.11M | (m) | 13.73% |
| 2022-09-30 | $943.14M | $2.25B | (m) | $230.43M | (m) | 41.97% |
| 2022-06-30 | $1.05B | $2.26B | (m) | $295.43M | (m) | 46.65% |
| 2022-03-31 | $1.42B | $2.28B | (m) | $297.94M | (m) | 62.37% |
| 2021-12-31 | $1.43B | $2.29B | (m) | $200.08M | (m) | 62.49% |
| 2021-09-30 | $1.59B | $2.29B | (m) | $104.04M | (m) | 69.62% |
| 2021-06-30 | $1.80B | $2.24B | (m) | $18.64M | (m) | 80.36% |
| 2021-03-31 | $1.46B | $2.19B | (m) | $21.29M | (m) | 66.68% |
| 2020-12-31 | $1.60B | $2.12B | (m) | $26.29M | (m) | 75.17% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $2.62B | $1.81B | (m) | $83.04M | (m) | 144.59% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $1.36B | $1.79B | (m) | $392.61M | (m) | 76.02% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |